You are here: Home / Public / News


Nanomedicine Translation around the globe - How to proper address regulatory processes for nanomedicines in different countries
Nanomedicine Award 2017: applications are now open!
The European Technology Platform for Nanomedicine (ETPN) and the EU-funded project ENATRANS, announce the launching of the 3rd edition of the Nanomedicine Award, which aims to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering thereby unmet medical needs. The winners in both categories will be announced and rewarded during the BIO-Europe conference in Berlin in November 2017. Apply Now!
First European Nanomed "Who's who"
The first "Who's who" dedicated to European SMEs in nanomedicine is about to go live!
Open call for applications to the Nanomedicine Translation Advisory Board
ENATRANS is pleased to announce that Round 4 of applications to the Nanomedicine Translation Advisory Board (nanomedTAB) is now open to companies, public and private research entities, and other organisations leading Nanomedicine R&D in Europe.
New Nanomedicine Digest published
After a well received pilot version of the Nanomedicine Digest, we are pleased to release the first official edition. Nanomedicine Digest will be released on a quarterly basis as means to promote relevant business news, scientific information, publications, events and success stories of nanomedicine in Europe.
Funding opportunity for Nanomedicine: new EuroNanoMed III Joint Call (2017)
Last option to submit proposals to H2020 SME-Instrument Phase 1 for SMEs in the healthcare biotechnology sector is on 09 November 2016
H2020 SME-Instrument: applications for Phase I (SME-1) grants will no longer be possible in topic SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare biotechnology sector
ENATRANS publishes a Compedium for successful translation - testing, regulation and reimbursement of Nanomedicine
The EU Project ENATRANS aims at providing support for the sucessful translation of Nanomedicine, in which issues such as clinical tests, regulation and reimbursement play a crucial role. With this compendium, guidance, links and contacts are provided for any team from academia or SMEs developing nanomedicine to timely and comprehensively address these issues.
EMA PRIME: an opportunity for the translation of Nanomedicine?
The European Medicines Agency (EMA) launched PRIME (PRIority MEdicines), a new scheme to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.
Interview of Dr. Klaus-Michael Weltring - Nanotechnology: a key to the future of medicine Interview
The COMPAMED Magazine interviewed the ENATRANS Partner Klaus-Michael Weltring to discuss about expectations, achievements, gaps and barriers for future medical products based on naotechnologies.
Round 3 of the TAB in sessions begins: apply before the 31st of July 2016!
EuroNanoMed secured funding under H2020 with the ERA-Net Cofund scheme
The third phase of EuroNanoMed (ENM III) has been positively evaluated by the European Commission and is currently undergoing the Grant Agreement Preparation phase.
EU-NCL- First call for characterisation of injectable nanomedicines addressing cancer
The recently established European Nanomedicine Characterisation Laboratory (EU-NCL) aims at providing critical infrastructure and characterisation services that are needed to analyse physical and chemical attributes, in vitro biological properties, and in vivo characteristics of emerging nanomedicines ready for translation and clinical trials.
Round 2 of the TAB in sessions begins: apply before the 8th of May!
Do you lead an innovative project in Nanomedicine? Apply to the Translation Advisory Board (TAB) before the 8th of May!
How will Nanomedicine revolutionize healthcare in the next 15 years?
The ETP Nanomedicine and the EuroNanoMed II joined forces to design and publish the new Nanomedicine Strategic Research and Innovation Agenda (SRIA), with the objective to address the challenges that European Healthcare systems are facing and to provide a concrete framework, including priorities for research, innovation and translation as well as a long term vision up to 2030 to foster the fruitful deployment of innovative Nanomedicine solutions.
Nanomedicine Award 2015: 2 projects awarded!
European Technology Platform on Nanomedicine (ETPN) and ENATRANS announced during the BIO-Europe Conference, the winner projects of the Nanomedicine Award 2015.
ENATRANS launches the first Translation Advisory Board (TAB), a new instrument to provide free of charge advice and support to ambitious international nanomedicine projects.
Nanomedicine Award's 2nd edition launches
EU-funded consortium, ENATRANS, and the the European Technology Platform for Nanomedicine (ETPN) have launched the second edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2015.
Filed under: